<DOC>
	<DOCNO>NCT00605033</DOCNO>
	<brief_summary>Post-marketing commitment European Medicines Agency conduct prospective , control study transfer Subutex Suboxone .</brief_summary>
	<brief_title>A Randomized Acceptability Safety Study Transfer From Subutex Suboxone Opioid- Dependent Subjects ( Study P04843 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Opioid-Related Disorders</mesh_term>
	<mesh_term>Substance-Related Disorders</mesh_term>
	<mesh_term>Naloxone</mesh_term>
	<mesh_term>Buprenorphine , Naloxone Drug Combination</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<criteria>Subjects must males nonpregnant , nonlactating female . Subjects must least 15 year age , either sex , race . Subjects ( and/or parent guardian subject age legal consent otherwise unable provide independent consent ) must demonstrate willingness participate study adhere dose visit schedule . Subjects must meet Diagnostic Statistical Manual Mental Disorders , Fourth Edition , Text Revision ( DSMIVTR ) criterion ( 18 ) opioid dependence . Subjects must receive maintenance treatment Subutex dose range 4 mg maximum dose permitted country labeling requirement , exceed 24 mg/day , least 1 month prior screen . Subjects must , accord selfreport , injected opioids four time month prior screen . Subjects must opioidnegative urine drug screening ( UDS ) result prior randomization . Each subject must confirm practice adequate contraception . Female subject childbearing potential must negative urine betahuman chorionic gonadotropin ( Î²hCG ) test prior enrollment study . Subjects treatment either Subutex Suboxone require protocol would inconsistent national labeling . Subjects unwilling unable comply requirement protocol ( eg , pending incarceration ) situation condition , opinion investigator , may interfere participation study . Subjects participate clinical study medication ( ) deliver . Subjects know allergy sensitivity naloxone . Subjects staff , affiliate , family member staff personnel directly involve study . Subjects must serious untreated Axis I DSMIVTR psychiatric comorbidity ( eg , actively suicidal homicidal , untreated schizophrenia , etc ) . Polysubstance abuse dependence exclude subject except case unauthorized significant benzodiazepine use require medical detoxification alcohol dependence require medical detoxification . Human immunodeficiency virus ( HIV ) positive subject clinical acquire immunodeficiency syndrome ( AIDS ) . Subjects treat generic buprenorphine .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>